Phastar and Beaconcure Announce Partnership, Enhance Data Review in Clinical Trials
New agreement leverages Beaconcure’s technology to streamline review processes.
Beaconcure, a provider of artificial intelligence-enabled clinical data validation and automation, has announced a new partnership with contract research organization, Phastar. This collaboration will enhance review processes in clinical trials by leveraging Beaconcure’s technology and Phastar’s experience in the clinical data analytics domain.1
"We are thrilled to collaborate with Phastar, a leader in clinical trial analytics. By leveraging Verify, Phastar is now equipped with a collaboration platform that reduces the potential for human error and increases efficiency and transparency, enabling faster study validation and approvals,” Ilan Carmeli, chief operating officer and co-founder, Beaconcure said in a press release. “By utilizing a unified platform, teams can integrate efforts, improve data integrity, and accelerate decision-making. These enhancements enable Phastar to manage internal communications and sponsor interactions more effectively, transforming clinical reviews, shortening review cycles, and expediting the delivery of treatments."
“We at Phastar prioritize our customers' needs and continuously seek innovative solutions to ensure timely access to lifesaving treatments for patients with urgent needs. Integrating Beaconcure’s Verify platform into our processes is an impactful step and will help unlock further innovations across clinical data reporting, reviewing, and submission stages,” Ping-Chung Chang, head of business transformation and China general manager, Phastar said in the press release. “We will utilize Verify to address critical areas in clinical review with automatically generated audit trails, streamlined data reporting delivery, and optimized workflow management.”
“Through this partnership, Beaconcure and Phastar are actively engaged in exploring new standards in the industry to increase speed and compliance in clinical trials,” Christine Oliver, CEO of Beaconcure said in the press release. “By partnering with Phastar and drawing Chang’s expertise, we’re not just deploying solutions—we’re creating a dynamic system that learns and improves over time.”
Reference
1. Phastar and Beaconcure Announce Partnership to Deliver Process Revolution in Clinical Data Review. News release. May 20, 2024. Accessed May 23, 2024. https://www.businesswire.com/news/home/20240520818825/en/Phastar-and-Beaconcure-Announce-Partnership-to-Deliver-Process-Revolution-in-Clinical-Data-Review
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
